T2 Biosystems Statistics
Total Valuation
T2 Biosystems has a market cap or net worth of 3.45 million. The enterprise value is 20.31 million.
| Market Cap | 3.45M |
| Enterprise Value | 20.31M |
Important Dates
The next estimated earnings date is Friday, May 2, 2025.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
T2 Biosystems has 28.05 million shares outstanding. The number of shares has increased by 659.51% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 28.05M |
| Shares Change (YoY) | +659.51% |
| Shares Change (QoQ) | +26.94% |
| Owned by Insiders (%) | 5.38% |
| Owned by Institutions (%) | 5.78% |
| Float | 15.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.47 |
| EV / Sales | 2.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.55 |
Financial Position
The company has a current ratio of 0.40
| Current Ratio | 0.40 |
| Quick Ratio | 0.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.52 |
| Interest Coverage | -13.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -84.85% |
| Return on Invested Capital (ROIC) | -138.95% |
| Return on Capital Employed (ROCE) | 655.67% |
| Revenue Per Employee | 67,938 |
| Profits Per Employee | -380,124 |
| Employee Count | 113 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 6.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.00% in the last 52 weeks. The beta is 0.33, so T2 Biosystems's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -96.00% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 1.87 |
| Relative Strength Index (RSI) | 45.11 |
| Average Volume (20 Days) | 115,941 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, T2 Biosystems had revenue of 7.68 million and -42.95 million in losses. Loss per share was -4.08.
| Revenue | 7.68M |
| Gross Profit | -19.03M |
| Operating Income | -41.66M |
| Pretax Income | -42.95M |
| Net Income | -42.95M |
| EBITDA | -41.40M |
| EBIT | -41.66M |
| Loss Per Share | -4.08 |
Balance Sheet
The company has 2.08 million in cash and 18.94 million in debt, giving a net cash position of -16.86 million or -0.60 per share.
| Cash & Cash Equivalents | 2.08M |
| Total Debt | 18.94M |
| Net Cash | -16.86M |
| Net Cash Per Share | -0.60 |
| Equity (Book Value) | -11.71M |
| Book Value Per Share | -0.62 |
| Working Capital | -14.65M |
Cash Flow
In the last 12 months, operating cash flow was -36.59 million and capital expenditures -26,000, giving a free cash flow of -36.62 million.
| Operating Cash Flow | -36.59M |
| Capital Expenditures | -26,000 |
| Free Cash Flow | -36.62M |
| FCF Per Share | -1.31 |
Margins
| Gross Margin | -247.83% |
| Operating Margin | -542.59% |
| Pretax Margin | -559.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
T2 Biosystems does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -659.51% |
| Shareholder Yield | -659.51% |
| Earnings Yield | -1,245.19% |
| FCF Yield | -1,061.52% |
Stock Splits
The last stock split was on October 13, 2023. It was a reverse split with a ratio of 0.01.
| Last Split Date | Oct 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
T2 Biosystems has an Altman Z-Score of -55.05. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -55.05 |
| Piotroski F-Score | n/a |